DK2509950T3 - 5-amino-4-hydroxypentoylamider - Google Patents
5-amino-4-hydroxypentoylamider Download PDFInfo
- Publication number
- DK2509950T3 DK2509950T3 DK10790938.4T DK10790938T DK2509950T3 DK 2509950 T3 DK2509950 T3 DK 2509950T3 DK 10790938 T DK10790938 T DK 10790938T DK 2509950 T3 DK2509950 T3 DK 2509950T3
- Authority
- DK
- Denmark
- Prior art keywords
- mmol
- solution
- formula
- added
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Claims (19)
1. Forbindelse med formlen I:
hvor R1 er halogen, Ci_4alkoxy, trifluormethoxy; R2 er en gruppe med formlen:
R3 er en gruppe med formlen:
R4 er en gruppe med formlen:
n er 0 eller 1; hvert A uafhængigt er CH eller N; R5 og R6 uafhængigt er hydrogen, Ci-4alkyl eller halogen; R7 er Ci-4alkyl eller Ci-4alkoxyCi-4alkyl; R8 er Ci-4alkyl eller Ci-4alkoxyCi-4alkyl; hvert R9 uafhængigt er Ci-4alkyl, cyclopropyl, trifluormethyl, Ci_4alkoxy eller dimethylamino; R10 er hydrogen, C^alkyl, cyclopropyl, trif luormethyl, Ci_ 4alkoxy eller dimethylamino; R11 er hydrogen eller Ci_4alkyl; de farmaceutisk acceptable additionssalte og de farmaceutisk acceptable solvater deraf.
2. Forbindelse ifølge krav 1, hvor R1 er halogen eller methoxy.
3. Forbindelse ifølge krav 1, hvor R1 er fluor eller chlor; hvilket fluor eller chlor er indsubstitueret i ortho-stillingen; eller R1 er methoxy; hvilket methoxy er indsubstitueret i meta-stillingen.
4. Forbindelse ifølge et hvilket som helst af kravene 1-3, hvor R2 er en gruppe med formlen
5. Forbindelse ifølge et hvilket som helst af kravene 1-3, hvor R2 er en gruppe med formlen
6. Forbindelse ifølge et hvilket som helst af kravene 1-5, hvor R5 er hydrogen, og R6 er halogen eller Ci_4alkyl; R5 er halogen, og R6 er hydrogen; R5 er halogen eller Ci-4alkyl, og R6 er hydrogen; eller R5 og R6 begge er hydrogen eller begge er halogen; R11 er Ci_4alkyl.
7. Forbindelse ifølge et hvilket som helst af kravene 1-5, hvor R5 er hydrogen, og R6 er fluor eller chlor; R5 er fluor eller chlor, og R6 er hydrogen; R5 er hydrogen, og R6 er methyl; R5 og R6 begge er hydrogen, eller R5 er chlor, og R6 er fluor; især hvor R5 er hydrogen, og R6 er fluor; R5 er chlor, og R6 er hydrogen; R5 er hydrogen, og R6 er methyl; R5 og R5 begge er hydrogen, eller R5 er chlor, og R6 er fluor; og R11 er methyl.
8. Forbindelse ifølge et hvilket som helst af kravene 1-7, hvor R3 er en gruppe med formlen
9. Forbindelse ifølge et hvilket som helst af kravene 1-7, hvor R3 er en gruppe med formlen
10. Forbindelse ifølge krav 9, hvor R8 er methyl eller 2- methoxyethyl.
11. Forbindelse ifølge krav 1-10, hvor R9 er Ci_2alkoxy eller dimethylamino.
12. Forbindelse ifølge et hvilket som helst af kravene 1-11, hvor R4 er en gruppe med den kemiske struktur, som er specificeret i krav 1, men hvor R9 er R9a i den første gruppe, R9 er R9b i den anden gruppe, R9 er R9c i den tredje gruppe, R9 er R9d i den fjerde gruppe, og R9 er R9e i den femte og i den sjette gruppe; hvilke grupper kan repræsenteres som følger:
hvor hvert A uafhængigt er CH eller N; eller hvor hvert A er CH; R9a er Ci_4alkoxy eller dimethylamino; R9b er Ci-4alkoxy eller dimethylamino; R9c er Ci-4alkoxy eller dimethylamino; R9d er Ci-4alkyl, cyclopropyl, trifluormethyl; R10 er hydrogen, Ci-4alkyl, cyclopropyl eller trifluormethyl; eller R10 er hydrogen, methyl, cyclopropyl eller trifluormethyl; hvert R9e uafhængigt er Ci-4alkyl, cyclopropyl, Ci_4alkoxy eller dimethylamino.
13. Forbindelse ifølge krav 12, hvor, i R9a, R9b, R9c, R9d eller R9e, Ci_4alkoxy er methoxy, og Ci_4alkyl er methyl.
14. Forbindelse ifølge et hvilket som helst af kravene 1-7, hvor R4 er: R9a A'"'" 4;'N * hvor A er CH, og R9a er methoxy eller dimethylamino.
15. Forbindelse ifølge krav 1, som har formlen
16. Forbindelse ifølge krav 1, som har formlen
17. Forbindelse ifølge krav 1, som har formlen
18. Forbindelse ifølge et hvilket som helst af kravene 1-17 til anvendelse som et lægemiddel.
19. Farmaceutisk sammensætning, som omfatter en effektiv mængde af en forbindelse med formlen I ifølge et hvilket som helst af kravene 1-17 og en bærer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09178979 | 2009-12-11 | ||
| EP10162370 | 2010-05-10 | ||
| PCT/EP2010/069328 WO2011070131A1 (en) | 2009-12-11 | 2010-12-10 | 5-amino- 4-hydroxypentoyl amides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2509950T3 true DK2509950T3 (da) | 2015-05-18 |
Family
ID=43534084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10790938.4T DK2509950T3 (da) | 2009-12-11 | 2010-12-10 | 5-amino-4-hydroxypentoylamider |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8592429B2 (da) |
| EP (1) | EP2509950B1 (da) |
| JP (1) | JP5797662B2 (da) |
| KR (1) | KR101771698B1 (da) |
| CN (1) | CN102770413B (da) |
| AP (1) | AP3217A (da) |
| AR (1) | AR079354A1 (da) |
| AU (1) | AU2010329867B2 (da) |
| BR (1) | BR112012013493B1 (da) |
| CA (1) | CA2783929C (da) |
| DK (1) | DK2509950T3 (da) |
| EA (1) | EA020758B1 (da) |
| ES (1) | ES2536774T3 (da) |
| HK (1) | HK1177454A1 (da) |
| IL (1) | IL219272A (da) |
| JO (1) | JO3090B1 (da) |
| MX (1) | MX2012006613A (da) |
| NZ (1) | NZ599916A (da) |
| PL (1) | PL2509950T3 (da) |
| PT (1) | PT2509950E (da) |
| SG (1) | SG181609A1 (da) |
| TW (1) | TWI485149B (da) |
| UY (1) | UY33098A (da) |
| WO (1) | WO2011070131A1 (da) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7111733B2 (ja) | 2017-03-16 | 2022-08-02 | 江蘇恒瑞医薬股▲ふん▼有限公司 | ヘテロアリール［４，３－ｃ］ピリミジン－５－アミン誘導体、その製造方法、およびその医薬の使用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89900A0 (en) * | 1988-04-12 | 1989-12-15 | Merck & Co Inc | Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them |
| EP0534511A1 (en) * | 1991-08-16 | 1993-03-31 | Merck & Co. Inc. | HIV protease inhibitors useful for the treatment of aids |
| CN1089269A (zh) * | 1993-01-04 | 1994-07-13 | 希巴-盖吉股份公司 | 新颖的作为治疗剂的5-氨基-4-羟基己酸衍生物 |
| US5733882A (en) * | 1994-01-17 | 1998-03-31 | Smithkline Beecham Corporation | Retroviral protease inhibitors |
| PT708085E (pt) * | 1994-10-19 | 2002-11-29 | Novartis Ag | Eteres antivirais de isosteros de substrato de aspartato protease |
| HU229224B1 (en) * | 2001-02-14 | 2013-09-30 | Tibotec Pharmaceuticals Ltd Little Island | 2-(substituted-amino)-benzothiazole sulfonamide compounds having broadspectrum hiv protease inhibitor activity and medicaments containing them |
| TWI286476B (en) * | 2001-12-12 | 2007-09-11 | Tibotec Pharm Ltd | Combination of cytochrome P450 dependent protease inhibitors |
| US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
| CN101115713A (zh) * | 2005-02-10 | 2008-01-30 | 美迪维尔公司 | 人类免疫缺陷性病毒蛋白酶抑制剂 |
| EP1851193B1 (en) * | 2005-02-10 | 2009-04-22 | Medivir AB | Hiv protease inhibitors |
| WO2007048557A1 (en) * | 2005-10-25 | 2007-05-03 | Medivir Ab | Protease inhibitors |
| JO2841B1 (en) * | 2006-06-23 | 2014-09-15 | تيبوتيك فارماسيوتيكالز ليمتد | 2-(substituted-amino) -benzothiazole sulfonamide as protease inhibitors HIV (HIV) |
| NZ573887A (en) * | 2006-07-21 | 2012-02-24 | Gilead Sciences Inc | Antiviral protease inhibitors |
-
2010
- 2010-11-30 JO JOP/2010/0423A patent/JO3090B1/ar active
- 2010-12-10 EP EP10790938.4A patent/EP2509950B1/en active Active
- 2010-12-10 CA CA2783929A patent/CA2783929C/en active Active
- 2010-12-10 PL PL10790938T patent/PL2509950T3/pl unknown
- 2010-12-10 NZ NZ599916A patent/NZ599916A/xx unknown
- 2010-12-10 AR ARP100104571A patent/AR079354A1/es active IP Right Grant
- 2010-12-10 MX MX2012006613A patent/MX2012006613A/es active IP Right Grant
- 2010-12-10 PT PT107909384T patent/PT2509950E/pt unknown
- 2010-12-10 AP AP2012006228A patent/AP3217A/xx active
- 2010-12-10 SG SG2012042552A patent/SG181609A1/en unknown
- 2010-12-10 ES ES10790938.4T patent/ES2536774T3/es active Active
- 2010-12-10 JP JP2012542555A patent/JP5797662B2/ja not_active Expired - Fee Related
- 2010-12-10 CN CN201080055694.9A patent/CN102770413B/zh active Active
- 2010-12-10 UY UY0001033098A patent/UY33098A/es not_active Application Discontinuation
- 2010-12-10 DK DK10790938.4T patent/DK2509950T3/da active
- 2010-12-10 KR KR1020127017093A patent/KR101771698B1/ko active IP Right Grant
- 2010-12-10 TW TW099143139A patent/TWI485149B/zh active
- 2010-12-10 EA EA201290487A patent/EA020758B1/ru not_active IP Right Cessation
- 2010-12-10 WO PCT/EP2010/069328 patent/WO2011070131A1/en active Application Filing
- 2010-12-10 US US13/515,187 patent/US8592429B2/en active Active
- 2010-12-10 AU AU2010329867A patent/AU2010329867B2/en active Active
- 2010-12-10 BR BR112012013493-0A patent/BR112012013493B1/pt active IP Right Grant
-
2012
- 2012-04-19 IL IL219272A patent/IL219272A/en active IP Right Grant
-
2013
- 2013-04-10 HK HK13104373.4A patent/HK1177454A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2114901B1 (en) | Hiv inhibiting 6-substituted pyrimidines | |
| KR101638326B1 (ko) | Ｒｈｏ 키나제 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 | |
| US11034718B2 (en) | C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors | |
| CN106045965A (zh) | 抑制hiv的5,6‑取代的嘧啶类化合物 | |
| DK2509950T3 (da) | 5-amino-4-hydroxypentoylamider | |
| WO2008107365A1 (en) | New compounds | |
| SK10332000A3 (sk) | Antivírusové zlúčeniny | |
| TWI480265B (zh) | ６－經取代之異喹啉類及異喹啉酮類 | |
| WO2008119773A1 (en) | Amide derivatives as inhibitors of aspartyl proteases | |
| US20120122920A1 (en) | Libraries of n-substituted-n-phenylethylsulfonamides for drug discovery | |
| OA16821A (en) | 5- Amino-4-hydroxypentoyl amides | |
| WO2024121183A1 (en) | New cyanopyridine khk inhibitor compounds | |
| OA18389A (en) | C-3 novel triterpenone with C-28 reverse amide derivatives as HIV inhibitors. | |
| WO2008135488A1 (en) | Aspartyl protease inhibitors |